NCT06024915 - A Study to Evaluate Drug-Drug Interaction of TQ05105 Tablets | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2023

Primary Completion Date

October 31, 2023

Study Completion Date

December 31, 2023

Conditions

Myelofibrosis

Interventions

DRUG

TQ05105 tablets

TQ05105 is a Janus kinase 2 (JAK2) inhibitor.

DRUG

Itraconazole capsule

Itraconazole is a strong inhibitor of cytochrome P450 3A (CYP3A).

DRUG

Rifampicin Capsule

Rifampicin is a strong inducer of CYP3A.

Trial Locations (1)

Shandong Provincial Hospital, Jinan